Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis. by Dika, Emi et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Computational Medicine Center Faculty Papers Computational Medicine Center 
5-12-2021 
Unraveling the role of microRNA/isomiR network in multiple 






See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/tjucompmedctrfp 
 Part of the Medicine and Health Sciences Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Computational Medicine Center Faculty Papers by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Emi Dika, Elisabetta Broseghini, Elisa Porcellini, Martina Lambertini, Mattia Riefolo, Giorgio Durante, 
Phillipe Loher, Roberta Roncarati, Cristian Bassi, Cosimo Misciali, Massimo Negrini, Isidore Rigoutsos, Eric 
R. Londin, Annalisa Patrizi, and Manuela Ferracin 
Dika et al. Cell Death and Disease          (2021) 12:473 
https://doi.org/10.1038/s41419-021-03764-y Cell Death & Disease
ART ICLE Open Ac ce s s
Unraveling the role of microRNA/isomiR network in
multiple primary melanoma pathogenesis
Emi Dika 1,2, Elisabetta Broseghini1, Elisa Porcellini1, Martina Lambertini1,2, Mattia Riefolo1, Giorgio Durante 1,
Phillipe Loher3, Roberta Roncarati4,5, Cristian Bassi4, Cosimo Misciali2, Massimo Negrini 4, Isidore Rigoutsos 3,
Eric Londin 3, Annalisa Patrizi1,2 and Manuela Ferracin 1
Abstract
Malignant cutaneous melanoma (CM) is a potentially lethal form of skin cancer whose worldwide incidence has been
constantly increasing over the past decades. During their lifetime, about 8% of CM patients will develop multiple
primary melanomas (MPMs), usually at a young age and within 3 years from the first tumor/diagnosis. With the aim of
improving our knowledge on MPM biology and pathogenesis, we explored the miRNome of 24 single and multiple
primary melanomas, including multiple tumors from the same patient, using a small RNA-sequencing approach. From
a supervised analysis, 22 miRNAs were differentially expressed in MPM compared to single CM, including key miRNAs
involved in epithelial–mesenchymal transition. The first and second melanoma from the same patient presented a
different miRNA profile. Ten miRNAs, including miR-25-3p, 149-5p, 92b-3p, 211-5p, 125a-5p, 125b-5p, 205-5p, 200b-3p,
21-5p, and 146a-5p, were further validated in 47 single and multiple melanoma samples. Pathway enrichment analysis
of miRNA target genes revealed a more differentiated and less invasive status of MPMs compared to CMs.
Bioinformatic analyses at the miRNA isoform (isomiR) level detected a panel of highly expressed isomiRs belonging to
miRNA families implicated in human tumorigenesis, including miR-200, miR-30, and miR-10 family. Moreover, we
identified hsa-miR-125a-5p|0|−2 isoform as tenfold over-represented in melanoma than the canonical form and
differentially expressed in MPMs arising in the same patient. Target prediction analysis revealed that the miRNA
shortening could change the pattern of target gene regulation, specifically in genes implicated in cell adhesion and
neuronal differentiation. Overall, we provided a putative and comprehensive characterization of the miRNA/isomiR
regulatory network of MPMs, highlighting mechanisms of tumor development and molecular features differentiating
this subtype from single melanomas.
Introduction
Melanoma is a malignant tumor that develops from
transformed melanocytes. The incidence of cutaneous mel-
anoma (CM) has been rising constantly in the past several
decades, reaching an age-standardized rate of 17.8, 16.1, and
35.8 per 100,000 in Northern Europe, North America, and
Australia-New Zealand, respectively (source IARC 2020).
CM accounts for 3–5% of all skin cancers, determining
up to 65% of the skin cancer-related deaths1. The
pathogenesis of CM is complex and poorly understood.
Risk factors include environmental, genetic, and pheno-
typic factors such as ultraviolet (UV) exposure, fair pho-
totypes, multiple dysplastic nevi, and a positive family/
personal history of CM2. Among them, a family history of
melanoma poses the highest risk for the development of
this tumor3,4.
The occurrence of multiple primary melanomas (MPMs)
in the same patient is thought to be related to a genetic
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susceptibility in association with lifestyle-correlated envir-
onmental factors. Thus, these patients represent a model of
high-risk CM occurrence. The excision of a primary CM
determines a risk up to 8.5%, to develop another CM in a
lifetime. The frequency of MPMs is reported to range
between 0.2% and 10%5–7 of all diagnosed melanoma
cases.
The above-reported rates may be underestimated, due
to the limited number of patients that undergoes a life-
time follow-up. Variability may also arise due to differ-
ences in environmental factors such as UV radiation
exposure across geographical regions. The risk of a sub-
sequent CM is highest in the first year following the
diagnosis of the primary CM; however, this risk remains
increased for at least 20 years8. The frequency of germline
mutations in melanoma susceptibility genes (CDKN2A
(cyclin-dependent kinase inhibitor 2A), CDK4 (cyclin-
dependent kinase 4), MITF (microphtalmia-associated
transcription factor), POT1 (protection of telomeres 1)/
ACD/TERF2IP, TERT, and BAP1) is lower than expected
in MPM patients7,9–11. The most frequent germline
mutations in MPMs are in CDKN2A gene, occurring in
8–15% of subjects diagnosed with MPM without familial
history and up to 40% of patients with hereditary CM
(familial melanoma Orpha-618)7,10,12,13. Mutations in
other susceptibility genes such as CDK4,MITF, and POT1
are less frequently detected14,15.
Despite the increased risk of multiple tumor develop-
ment, the debate about the prognosis of MPM patients is
still opened. On one hand, Doubrovsky et al.16 observed a
favorable prognosis in patients with MPM; on the other
hand, a worse prognosis for these patients was recently
reported by El Sharouni et al.17. Therefore, a better
characterization of MPM pathogenesis and biological
features is of the outmost importance.
The dysregulation of small noncoding RNAs, specifi-
cally microRNAs (miRNAs, 18–22 nucleotides in length),
plays a significant role in tumorigenesis, including mela-
noma onset and progression18. MiRNAs regulate multiple
and specific target genes, determining an oncogenic or
tumor-suppressive function, being implicated in the pro-
liferation, apoptosis, and tumor progression. Moreover,
miRNA global expression profile faithfully classifies nor-
mal and pathological cells and tissues19,20, with the
advantage to be obtainable also from formalin-fixed and
paraffin-embedded (FFPE) tissues21.
Information on miRNA sequences are cataloged in
miRBase database22, which reports a unique mature
sequence for each miRNA, the so-called canonical form.
Recently, evidences from deep-sequencing experiments
suggested that miRNAs could have modifications in
length and sequence in human tissues. These miRNA
isoforms are called isomiRs23. The exact mechanisms by
which isomiRs are generated is not fully understood; it is
most likely due to alternative Drosha and/or Dicer clea-
vage of the precursor molecules24. Another mechanism
that could explain isomiR biogenesis is posttranscriptional
modifications made by nucleotidyl transferase, which adds
nucleotides to pre-miRNA or mature miRNA ends25–27.
IsomiRs can differentiate from the canonical counterpart
in stability and abundance, and affects different down-
stream pathways28. It was suggested that canonical miR-
NAs and their isomiRs function cooperatively to target
common biological pathways23.
In this study, we investigated the global miRNA and
isomiR expression profile of MPMs using an unbiased
small RNA-sequencing (RNA-seq) approach. A compar-
ison of familial/non-familial MPM vs. single primary
melanoma miRNome was established, to investigate the
possible similarities. Moreover, MPM miRNA profile was
assessed matching multiple tumors from the same patient.
Finally, we characterized the miRNA/isomiR regulatory
network in MPM by bioinformatic analysis.
Materials and methods
Clinical samples
A retrospective series of 47 samples from 29 patients
was collected. Patients were selected among those refer-
ring to the melanoma center of the Dermatology Unit at
Bologna University Hospital. The study was approved by
Comitato Etico Indipendente di Area Vasta Emilia Centro
- CE-AVEC, Emilia-Romagna Region (number 417/2018/
Sper/AOUBo). Before study entry, all the patients pro-
vided written and voluntary informed consent for inclu-
sion, collection, and use of clinical–pathological data and
samples, and data privacy.
Histopathologic specimens were evaluated by two
dermato-pathologists and were classified into three
groups: benign nevi (BN), single primary CM, and MPM.
Group 1 (n= 3) includes BN of three patients with no
prior diagnosis of CM or non-melanoma skin cancer and
a follow-up of at least 10 years. Group 2 (n= 35) includes
MPM samples from 17 patients with prior diagnosis of ≥2
CMs. Three out of 17 patients had a positive family his-
tory of CM. Group 3 (n= 9) includes nine samples from
CM patients with no history of prior CMs and a follow-up
of at least 10 years.
Tumor and nevi samples were FFPE. For each sample, five
to six tissue sections on glass slides were obtained. One
section was stained with hematoxylin–eosin and was
examined by an expert pathologist to select the tumor/nevus
area, which was macrodissected before RNA extraction.
RNA extraction
RNA was isolated from 10 µm-thick FFPE sections
using miRNeasy FFPE kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Depar-
affinization was performed with xylene followed by an
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ethanol wash. RNA was eluted in 30 µL of RNAse-free
water and quantified, then stored at −80 °C.
Small RNA sequencing
We analyzed 3 BN, 4 single CM, and 17 MPMs or familial
melanomas from 8 different patients. The 24 small RNA
libraries were generated using TruSeq Small RNA Library
PrepKit v2 (Illumina, San Diego, CA, RS-200-0012/24/36/
48), according to manufacturer’s indications. Briefly, 35 ng of
purified RNA was ligated to RNA 3′- and 5′-adapters, con-
verted into cDNA, and amplified using Illumina primers
containing unique indexes for each sample. High Sensitivity
DNA (HS-DNA) kit (Agilent Technologies, Santa Clara, CA,
USA5067-4626) was adopted for library quantifications
using Agilent Bioanalyzer (Agilent Technologies) and the 24
DNA libraries were combined in equal amount to generate a
libraries pool.
Pooled libraries underwent to size selection employing
magnetic beads (Agencourt, Beckman Coulter, Brea, CA)
and amplicons with a length in the 130–160 bp range
were recovered.
Finally, 20 pM of pooled libraries, quantified using the
HS-DNA Kit (Agilent Technologies), were denatured,
neutralized, and combined with a Phix control library
(standard library normalizator). A 1.8 pM final con-
centration of pooled libraries (obtained by dilution with a
dedicated buffer as described in Illumina protocol
guidelines) was obtained and sequenced using Next-
Seq500/550 High Output Kit v2 (75 cycles) (Illumina, FC-
404-2005) on the Illumina NextSeq500 platform.
Raw base-call data were demultiplexed using Illumina
BaseSpace Sequence Hub and converted to FASTQ format.
After a quality check with FastQC tool29, the adapter
sequences were trimmed using Cutadapt30, which was also
used to remove sequences shorter than 16 nucleotides and
longer than 30 nucleotides. Reads were mapped using the
STAR algorithm31. Only reads that mapped unambiguously
to the reference genome retrieved from miRBase 21 data-
base (at least 16 nucleotides aligned, with a 10% mismatch
allowed) were used for the downstream analyses. Raw
counts from mapped reads were obtained using the htseq-
count script from the HTSeq tools32. Counts were nor-
malized using DESeq2 bioconductor package33. Next-
generation sequencing (NGS) raw data (FASTQ format)
are available through European Nucleotide Archive (ENA)
with the following accession number: PRJEB35819.
Quantitative PCR
miRCURY LNA assay
RNA from 47 samples was converted to cDNA using
miRCURY LNA RT kit (Qiagen, catalog number 339340).
Reverse-transcription (RT) reaction was performed as
follows: 2 µL miRCURY RT Reaction Buffer, 4.5 µL
RNase-free water, 1 µL miRCURY RT Enzyme Mix, 0.5 µL
UniSp6 spike-in, and 2 µL template RNA (5 ng/µL). RT
cycling protocol consisted in 60min at 42 °C, 5 min at
95 °C, and cooling at 4 °C. cDNA samples were stored at
−20 °C. RT-quantitative PCR (qPCR) was performed
using miRCURY LNA SYBER Green PCR kit (Qiagen,
catalog number 339346) and primers from miRCURY
LNA miRNA PCR Assays (Qiagen, catalog number
339306): hsa-miR-21-5p (catalog number YP00204230),
hsa-miR-25-3p (catalog number YP00204361), hsa-miR-
125b-5p (catalog number YP00205713), hsa-miR-146a-5p
(catalog number YP00204688), hsa-miR-205-5p (catalog
number YP00204487), hsa-miR-149-5p (catalog number
YP00204321), hsa-miR-92b-3p (catalog number YP0020
4384), hsa-miR-200b-3p (catalog number YP00206071),
hsa-miR-211-5p (catalog number YP00204009), hsa-miR-
16-5p (catalog number YP00205702), and hsa-miR-125a-
5p (catalog number YP00204339). For each miRNA tar-
get, cDNA was diluted at the ratio of 1 : 80 with the
exception of miR-92b-3p, for which cDNA was diluted 1 :
4. Cycling program consisted in 10 min at 95 °C and 2-
step cycling (40 cycles) of denaturation (10 s at 95 °C), and
combined annealing/extension (60 s at 60 °C). Each assay
was tested in triplicate. Raw Cq values were obtained from
BioRad CFX software. Interplate calibrators were used to
standardize miRNA Cq values across plates. miR-16-5p
was selected as reference miRNA due to its stability across
samples in NGS experiment. The calculation of relative
expression was performed using 2−ΔCt methods.
miSCRIPT assay (sum of 5′- and 3′-isoforms quantification)
RNA from 39 samples was reverse transcribed using
miSCRIPT HiSpec Buffer frommiSCRIPT II RT kit (Qiagen,
catalog number 218161) according to the manufacturer’s
instructions. Specifically, RT reaction was prepared in a total
reaction volume of 10 µL with 2 µL miScript HiSpec Buffer,
1 µl miScript Nucleics Mix, 4 µL RNase-free water, 1 µL
miScript Reverse Transcriptase Mix, and 2 µL template
RNA (5 ng/µL). RT cycling protocol consisted in 60min at
37 °C, 5min at 95 °C, and cooling at 4 °C. cDNA samples
were stored at −20 °C. RT-qPCR was performed using
miSCRIPT SYBER Green PCR kit (Qiagen, cod. number
218073) and primers from miSCRIPT Primer Assays (Qia-
gen, catalog number 218300): hsa-miR-125a-5p (cod. num-
ber MS00003423), hsa-miR-200b-3p (cod. number
MS00009016), RNA U6 (RNU6) (cod. number
MS00033740). Reaction mix was prepared with 10 µL
QuantiTect SYBR Green PCR Master Mix, 2 µL miScript
Universal Primer, 2 µL miScript target Primer, 3 µL RNase-
free water, and 3 µL cDNA template (1 : 40).
Cycling program consisted in 15min at 95 °C and a 3-
step cycling (40 cycles) of denaturation (15 s at 94 °C),
annealing (30 s at 55 °C), and extension (30 s at 70 °C).
Each assay was tested in triplicate. Raw Cq values were
obtained from BioRad CFX software. Small nuclear RNU6
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was used as reference gene. The calculation of relative
expression was performed using 2−ΔCt methods.
IsomiR quantification
IsomiRs were identified in our NGS dataset of 24 sam-
ples as described in Loher et al.34. Briefly, sequence reads
were quality trimmed using the Cutadapt tool30 and
mapped unambiguously using SHRIMP235 to the human
genome assembly GRCh38. During the mapping, no
insertions or deletions and, at most, one mismatch was
permitted. IsomiRs were identified as done previously34,36.
For The Cancer Genome Atlas (TCGA) isomiR analysis,
short RNA-seq Aligned BAM files were downloaded from
the Genomic Data Commons Data Portal (https://portal.
gdc.cancer.gov/) for all 32 cancer types. IsomiR profiles
were generated using the same approach as described in
Loher et al.34. To simplify the labeling of the isomiRs, we
used the annotation system developed by Loher et al.34.
This nomenclature specifies the name of the canonical
miRNA, the start site (5′-end) of the isomiR compared to
the canonical miRNA sequence in miRBase, the end site
(3′-end), and the eventual insertion of uracil. In particular,
to annotate the start and end site of an isomiR, a negative
(−) or positive sign (+) followed by the number of
nucleotides is used to indicate the isomiR nucleotide shift
in the 5’ or 3’ direction, respectively, if compared to the
canonical miRNA sequence. Zero indicate the same ter-
minus of the canonical miRNA sequence. We quantified
isomiR abundances in reads per million. Only reads that
passed quality trimming and filtering, and could be
aligned exactly to miRNA arms were used in the
denominator of this calculation. IsomiR targets were
predicted using the RNA22 algorithm37 and targets were
allowed to be present in the 5′-untranslated region (UTR),
coding sequence, and 3′-UTR of the candidate mRNA.
We selected only those targets that had a p-value < 0.01
and a predicted binding energy <−16 kcal/mol, while also
allowing G : U wobbles and bulge’s within the seed
region.
Statistical analysis
Normalized sequencing data were imported and ana-
lyzed in Genespring GX software (Agilent Technologies).
Differentially expressed miRNAs were identified using a
fold-change >1.5 filter and moderated t-test (false dis-
covery rate 5% with Benjamini–Hochberg correction) in
CM vs. MPM comparison, and using fold-change >1.2 and
paired t-test (p < 0.05) in first vs. second MPM compar-
ison. Cluster analysis was performed using Manhattan
correlation as a similarity measure. Principal component
analysis (PCA) was performed on 24 samples using all
human miRNAs detected by NGS analysis (n= 1629).
Graphpad Prism 6 (GraphPad Software, San Diego, CA)
was used for statistical analyses. Group comparison was
performed using unpaired t-test, when data had a normal
distribution, with or without Welch’s correction accord-
ing to the significance of the variance test. Data that did
not present a normal distribution were compared using
Mann–Whitney non-parametric test. Paired t-test was
used to compare miRNA expression level in the first and
second melanomas from the same patient. Two-tailed p-
values are used in text and figures. Association of gene
expression with overall survival in TCGA skin cutaneous
melanoma (SKCM) cohort was obtained using the
Oncolnc website (http://www.oncolnc.org) and log rank
test was used to calculate the p-value.
Pathway analysis
Pathway and network analysis of differentially expressed
miRNAs, miR-125a-5p isoforms, and their targets was
investigated using the web-based software MetaCore
(Clarivate, Philadelphia, PA). A p-value of 0.05 was used
as a cutoff to determine significant enrichment.
Results
Patient characteristics
Demographic, clinical, and pathological features of
47 samples from 29 individuals are summarized in Table
1. Samples from 15 individuals (8 with MPMs, 4 with
CMs, and 3 with BNs) were investigated with NGS (N=
24). All the samples were used for the validation of NGS
results. Nine patients had single CM and 10 years of
follow-up; 17 developed more than one primary mela-
noma in an average time of 33 months (range 3–98).
MPM patients were tested for germline genetic alterations
in CDKN2A, CDK4, and MITF gene38, and only one
patient was found to have a germline CDKN2A mutation
(c.249 C > A p.His83Gln exon 2) of unknown clinical
significance.
The miRNA profile of MPM
The global miRNA profile of 17 MPMs, obtained from 8
patients, was analyzed using a small RNA-seq approach.
For each MPM patient, we analyzed the first and second
primary tumor, and for one case also a third one. Three
patients had a family history of melanoma. We compared
the global miRNA profile of 17 MPMs vs. 4 single mela-
nomas and 3 BN. From the small RNA-seq data, we
identified 1629 mature miRNAs expressed in melanoma
and nevus cells. The unsupervised PCA of all miRNAs
and all samples (n= 24) revealed that familial and non-
familial MPMs have a greatly overlapping miRNA profile
(Fig. 1a), which is different from single CM and BN.
Indeed, a statistical comparison between familial and non-
familial MPMs did not provide any significant result.
Therefore, we considered familial and non-familial mel-
anomas as a unique group in all subsequent analyses.
From the PCA analysis, we can already observe that
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MPMs displayed an miRNA profile intermediate between
BN and CMs. When we compared multiple and single
melanoma tumors, we obtained a markedly different
miRNA expression profile and a list of 22 miRNAs dif-
ferentially expressed (adjusted p < 0.05, Supplementary
Table 1), which are represented with a Volcano plot in
Fig. 1b. Cluster analysis of these samples based on the
expression of the 22 differentially expressed miRNAs
confirmed the separation between single and multiple
tumors (Fig. 1c). We evaluated the miRNA profile in
MPM groups using a paired statistical analysis. Despite
the similarities between the two matching MPMs, a var-
iation in miRNA expression was observed (Fig. 1b). Spe-
cifically, 37 miRNAs were differentially expressed between
the first and second MPM (paired t-test, p < 0.05, Sup-
plementary Table 2), whose expression clearly separate
the groups in the cluster analysis (Fig. 1d).
Validation of miRNA differential expression in single and
multiple primary melanomas, and paired primary tumors
from the same patient
Nine miRNAs were selected for an independent valida-
tion using quantitative RT-PCR in 47 samples including
BN, CM, and first and second MPM. Specifically, we
included six miRNAs differentially expressed between CM
and MPM (miR-21-5p, miR-25-3p, miR-125b-5p, miR-
146a-5p, miR-205-5p, and miR-149-5p) and four that are
dysregulated between the first (MPM 1st) and second
(MPM 2nd) melanoma from the same MPM patient (miR-
149-5p, miR-92b-3p, miR-200b-3p, and miR-125a-5p).
According to the small RNA-seq results, an upregulated
expression of miR-21-5p, miR-25-5p, and miR-146a-5p,
and a downregulated expression of miR-125b-5p, miR-
149-5p, and miR-205-5p in CM compared to MPM were
expected. In MPM samples, all selected miRNAs are
upregulated in the MPM 2nd compared to MPM 1st. In
the validation experiment, we included also miR-211-5p,
whose genetic locus is located inside the melastatin-1/
TRPM1 (transient receptor potential cation channel,
subfamily M, member 1 protein) gene and whose
expression is particularly high in nevi. The expression of
this miRNA was higher in BN, with borderline statistical
significance when compared to CM or MPM in our
NGS data.
The validation was performed in a cohort of 29 patients,
as described in Table 1, using miR-16-5p as a reference
gene due to its invariant expression in NGS data.
Expression distributions of selected miRNAs in BN, CM,
Table 1 Patient characteristics.
Benign nevi (BN) Cutaneous
melanoma (CM)
Multiple primary melanoma (MPM)
MPM 1st MPM 2nd MPM 3rd
Gender (n, %)
Male 0 (0%) 3 (33.3%) 13 (76.5%)
Female 3 (100%) 6 (66.7%) 4 (23.5%)
Total 3 9 17
Histology (n, %)
Compound melanocytic nevus 2 (66.7%) - - - -
Dermal nevus 1 (33.3%) - - - -
Superficial spreading melanoma - 4 (44.5%) 15 (88.2%) 16 (94.1%) 1 (100%)
Superficial spreading melanoma with
vertical growth phase
- 3 (33.3%) 1 (5.9%) - -
Nodular melanoma - 2 (22.2%) 1 (5.9%) - -
Nevus-associated melanoma - 0 - 1 (5.9%) -
Age at first diagnosis (n, %)
<50 - 7 (77.8%) 8 (47%)
≥50 - 2 (22.2%) 9 (53%)
Mean (range) - 59 (29–85) 53 (30–80)
Localization (n, %)
Trunk 3 (100%) 6 (66.7%) 13 (76.5%) 14 (82.4%) 1 (100%)
Limbs - 2 (22.2%) 3 (17.6%) 3 (17.6%) -
Head and neck - 1 (11.1%) 1 (5.9%) - -
Breslow thickness (n, %)
<0.8 mm - 1 (11.1%) 12 (70.6%) 17 (100%) 1 (100%)
≥0.8 mm - 8 (88.9%) 5 (29.4%) 0 (0%) -
Family history of melanoma (n, %)
Yes - - 3 (17.6%)
No - - 14 (82.4%)
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and MPM samples are represented in Fig. 2. The sig-
nificant upregulation of miR-21-5p in CM vs. MPM was
confirmed. A statistically significant miR-25-3p down-
regulation in CM and MPM compared to BN was
observed, while miR-146a-5p was downregulated in MPM
compared to BN and CM. A similar expression level in
CM and BN, and a trend toward increased expression in
MPM were obtained for miR-125b-5p. A significant
upregulation of miR-200b-3p, miR-205-5p, and miR-149-
5p was observed in MPM compared to CM. As expected,
miR-211-5p is progressively downregulated in multiple
and single melanomas (Fig. 2).
The differential expression of miR-149-5p, miR-92b-3p,
miR-200b-3p, and miR-205-5p between paired first and
second melanomas from the same patient is represented
in Fig. 3. The expected significant upregulation for miR-
149-5p, miR-92b-3p, miR-205-5p, and miR-200b-3p in
MPM 2nd tumor was confirmed in this larger group of
samples.
Functional annotation of MPM miRNA signature
The list of 22 miRNAs differentially expressed in mul-
tiple vs. single melanomas was uploaded in MetaCore
software to identify both the pathways that are sig-
nificantly regulated by these miRNAs (Supplementary
Table 3) and the most significant miRNAs/targets net-
works (Supplementary Fig. 1a).
MPMs were found to have a higher expression of
epithelial–mesenchymal transition (EMT)-associated
miRNAs (miR-149-5p, miR-200 family, and miR-205-5p)
compared to single CM and even nevi (Figs. 2 and 4).
miR-149-5p inhibits FOXM139, whereas miR-200 family
and miR-205-5p target ZEB1/TCF8 and ZEB2/SIP1 genes,
and by doing so they inhibit the EMT pathway. Therefore,
this pathway appears to be specifically activated in single
melanomas (Fig. 4).
From MetaCore network analysis, three hub genes
(TLR4, ITGA6, and BTG2) were identified as targeted by
multiple miRNAs, either up- or downregulated in
Fig. 1 Single and multiple melanoma classification based on the miRNA profile. a Unsupervised principal component analysis (PCA) of
24 samples based on the expression profile of all the miRNAs detected at NGS analysis. Familial (yellow) and non-familial (cyan) multiple primary
melanomas display a similar microRNA profile, which is different from single cutaneous melanoma (red) and benign nevi (gray). b Cluster analysis and
heatmap representation of multiple and single melanoma based on the expression of 22 differentially expressed miRNAs (moderated t-test, adjusted
p < 0.05). Red and green color represent the increased or reduced expression across samples. c Cluster analysis and heatmap representation of the
first and second melanomas from the same patient based on the expression of 37 differentially expressed miRNAs (paired t-test, p < 0.05). Red and
green color represent the increased or reduced expression across samples. d Volcano plot showing the differentially expressed miRNAs at the
selected p-value and fold-change combinations.
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multiple melanomas. When we assessed the association of
TLR4, ITGA6, and BTG2 gene expression with melanoma
prognosis, we observed that their higher expression
(median cutoff) was significantly associated with a worse
overall survival in TCGA SKCM cohort of 458 samples
(Supplementary Fig. 1b).
IsomiR analysis revealed that a miR-125a-5p isoform is
dysregulated in MPM
Interestingly, miR-125a-5p differential expression in
MPM was not confirmed by qPCR technology and we
wondered about a possible explanation. We observed that
the reads generated by the small RNA-seq experiment and
attributed to mature miR-125a-5p following the standard
matching pipeline were actually shorter by 1, or most
frequently 2 nucleotides (lack of GA at the 3′-end) in all
samples (Supplementary Fig. 2a).
We analyzed the miRNA variants (isomiRs) expres-
sion level in our NGS data. We found 90 miRNAs with
sequence and length heterogeneity, generating 324
different isomiRs, and 40 canonical miRNAs without
any isomiR. In addition, we found and excluded 40
isomiRs named “orphan,” because their canonical
miRNA sequences could not be detected in our NGS
data. Orphan isomiRs can originate by the addition of
non-templated base pairs, from either uridylation,
adenylation, or other modifications. As these bases are
posttranscriptionally added, the full “orphan” isomiR
cannot be found in the genome. In addition, Cloonan
et al.23 suggested that orphan isomiRs could also be
mis-annotated mature miRNAs. Given their still
unknown biological role, we did not carry out any
further investigation on this class.
For each isomiR, we calculated the average expression in all
sequenced samples and the ratio between each isomiR and
its canonical miRNA. As the low expressed isomiRs are
bound to have a marginal role, we focused on highly
expressed isomiRs that could potentially affect the target
gene regulation of the canonical counterpart. We obtained a
panel of 17 isoforms that are 3- to 10-fold more abundant
than their canonical forms (Table 2). Among them, we
noticed an enrichment of isomiRs belonging to three
important miRNA family: miR-30 family, miR-200 family,
and miR-10 family. For each family member, we analyzed the
expression of its isomiRs and canonical forms (Supplemen-
tary Figs. 3–5). The most representative miR-30 family iso-
miRs are 3′-variants with the addiction of 1 or 2 nucleotides
(Supplementary Fig. 3). On the contrary, the most expressed
miR-10 family isomiRs are shorter 3′-isoforms (−1 or −2
nucleotides) (Supplementary Fig. 4). miR-200 family pre-
sented highly expressed 3′-isoforms, both with addiction or
deletion of nucleotides (Supplementary Fig. 5).
Fig. 2 Differential microRNA expression in benign nevi (BN), cutaneous melanoma (CM), and in multiple primary melanoma (MPM). Box
and whiskers graph representation of nine microRNAs differentially expressed in single and multiple primary melanomas (P < 0.05). MPM shows
higher expression levels of miR-205-5p, miR-200b-3p, and miR-149-5p compared to CM, and higher expression of miR-92b-3p compared to BN. MPM
downregulates miR-21-5p compared to CM and miR-146a-5p compared to CM and BN. BN upregulates miR-25-3p and miR-211-5p compared to CM
and MPM. Each miRNA was tested in triplicate by quantitative RT-PCR. Relative miRNA expression was normalized on invariant miR-16-5p. The bar
shows minimum and maximum values; superimposed points represent all individual values.
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In the group of 17 miRNAs with highly expressed iso-
miRs, we found two isomiRs whose canonical miRNA was
differentially expressed in first vs. second MPMs: miR-
125a-5p and miR-200b-3p.
Quite peculiarly, miR-125a-5p canonical form and hsa-
miR-125a-5p|0|−2 isoform show opposite expression
trends in nevi, single primary melanomas, and MPMs
(Fig. 5a). On the other hand, hsa-miR-200b-3p|0|+1 and
its canonical form showed the same upregulated expres-
sion in MPM 2nd compared to the MPM 1st
(Fig. 5b).
We studied two different technical approaches for iso-
miR quantification based on commercial RT-qPCR kits
(miRCURY LNA and miSCRIPT), in all samples. Speci-
fically, miRCURY LNA assay design was used to quantify
the canonical form (including the 5′-isoforms, which are
Fig. 3 Differential microRNA expression in first vs. second melanoma from the same patient. Before–after plot showing the paired expression
of 4 selected microRNAs in 17 multiple primary melanoma (MPM) patients. miR-92b-3p, miR-205-5p, miR-200b-5p, and miR-149-5p are significantly
downregulated in the first melanoma compared to the second melanoma. Each miRNA was tested in triplicate by quantitative RT-PCR. Relative
miRNA expression was normalized on invariant miR-16-5p. Paired t-test p-value is reported.
Fig. 4 MetaCore pathway analysis showing the involvement of differently expressed miRNAs in epithelial–mesenchymal transition (EMT).
EMT pathway representation with regulating miRNAs. Log ratio of miRNA expression level in CM/BN (1), MPM/BN (2), and MPM/CM (3) is visualized on
the maps as a thermometer-like figure. Upward thermometers have a red color and indicate upregulated signals, and downward (blue) ones indicate
downregulated expression level of specific microRNAs. “M” indicates microRNA binding (regulation of gene expression by binding of microRNA to
target mRNA), whereas “TR” indicates Transcription regulation (physical binding of a transcription factor to target gene’s promoter). MPM showed
higher expression levels of microRNAs involved in the inhibition of epithelial–mesenchymal transition (EMT), including miR-205-5p and miR-200b-3p.
(BN, benign nevi; CM, cutaneous melanoma; MPM multiple primary melanoma).
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not abundant/detected in our NGS data), whereas miS-
CRIPT assay was used to detect all the isoforms, as a
consequence of the use of a universal 3′-primer during
miRNA amplification (Supplementary Fig. 2b). As
expected, the two assays validated miR-200b-3p differ-
ential expression, providing the same results obtained by
NGS data. In fact, both the canonical miRNA and hsa-miR-
200b-3p|0|+1 showed an upregulation in MPM 2nd com-
pared to the MPM 1st (Fig. 5e, f). For miR-125a-5p, miR-
CURY LNA assay did not quantify the predominant 3′-
isomiRs; therefore, the NGS data could not be validated (Fig.
5c, d). Results revealed a lack of variation between single and
multiple melanomas, and a higher expression in the first vs.
second melanoma using (Fig. 5c, d). Given the high pre-
dominance of the of hsa-miR-125a-5p|0|−2 isoform in our
samples, we assumed that the miSCRIPT assay could pro-
vide a bona fide quantification of hsa-miR-125a-5p|0|−2
isomiR. As expected, an increase in miR-125a-5p level in
MPMs vs. CMs and in the second tumor from the same
patient was observed (Fig. 5c, d). As a further confirmation
of our findings, we examined the expression of hsa-miR-
125a-5p|0|−2 (isomiR, 22 nt long) and 0|0 (canonical
miRNA, 24 nt long) isoforms across all TCGA tumor types
and discovered an overall higher expression of the shorter
form in human cancers and a specifically altered ratio of the
two forms in SKCM (CM cohort), which shows the largest
variation (Fig. 6).
miR-125a-5p miRNA/isomiR regulated different target
genes
We ran a bioinformatics analysis to predict the impact
of miR-125a-5p 3′-isomiR in target gene binding. We used
RNA22 algorithm to obtain the list of putative pairing
sites for miR-125a-5p canonical form (N= 1342) and its
3′-isoform miR-125a-5p|0|−2 (N= 971) (Supplementary
Table 4). The shorter miR-125a-5p isoform loses the
ability to bind a fraction of canonical miR-125a-5p|0|0
targets (Supplementary Table 5). The predicted target
genes were submitted for functional annotation to
MetaCore suite. Significantly enriched pathways and
networks were identified for common and specific targets
of canonical miR-125a-5p canonical (miR-125a-5p|0|0)
and its 3′-isomiR (miR-125a-5p|0|−2) (Supplementary
Table 6), revealing a loss of targeting for miR-125a-5p|0|
−2 of genes involved in nervous system development,
neurogenesis, and neuronal differentiation. IsomiR miR-
125a-5p|0|−2 no longer targets key genes involved in cell
adhesion and migration (Ephrin receptors, Netrin 1) or
intracellular signaling (PIK3C2B).
Discussion
The risk of melanoma development is influenced by
environmental and genetic factors2. Families with history
of melanoma could have a germline mutation that confers
hereditary susceptibility and this is particularly
Table 2 IsomiRs most represented in melanoma and nevi small RNA-sequencing data.
IsomiR Type IsomiR expression (mean) Canonical miRNA expression (mean) Ratio isomiR/canonical miRNA
hsa-miR-141-3p|0|−1 End-site isomiR 200.33 8.65 23.15
hsa-miR-222-3p|0|+3 End-site isomiR 154.64 9.05 17.08
hsa-miR-30a-5p|0|+2 End-site isomiR 211.95 13.33 15.90
hsa-miR-125a-5p|0|−2 End-site isomiR 765.69 56.46 13.56
hsa-miR-30d-5p|0|+2 End-site isomiR 416.87 41.32 10.09
hsa-miR-10b-5p|0|−1 End-site isomiR 2950.88 357.98 8.24
hsa-miR-27a-3p|0|−1 End-site isomiR 167.78 30.55 5.49
hsa-miR-30a-5p|0|−2 End-site isomiR 72.12 13.33 5.41
hsa-miR-222-3p|0|+4 End-site isomiR 46.98 9.05 5.19
hsa-miR-19b-3p|0|−1 End-site isomiR 52.06 11.59 4.49
hsa-miR-30c-5p|0|+1 End-site isomiR 151.53 34.28 4.42
hsa-miR-26b-5p|0|+1 End-site isomiR 172.47 39.32 4.39
hsa-miR-222-3p|0|+2 End-site isomiR 36.83 9.05 4.07
hsa-miR-10a-5p|0|−1 End-site isomiR 636.58 184.52 3.45
hsa-miR-30a-5p|0|+1 End-site isomiR 45.68 13.33 3.43
hsa-miR-30d-5p|0|+1 End-site isomiR 140.07 41.32 3.39
hsa-miR-200b-3p|0|+1 End-site isomiR 44.86 13.26 3.38
Dika et al. Cell Death and Disease          (2021) 12:473 Page 9 of 15
Official journal of the Cell Death Differentiation Association
demonstrated in families where more than one member
develop MPMs40,41. Nowadays, most studies report a very
low prevalence of mutation in CDKN2A and CDK4 genes
in multiple melanoma patients, especially in Southern
Europe countries9. Although MPM patients often report
similar sun exposure experiences, the high percentage of
atypical nevi in these patients and their family members,
the frequent family history of melanoma, as well as the
early onset of melanoma (young age) suggest that pre-
disposing factors are involved in the development of the
disease42. However, cases of MPM in individuals without
familial history of melanoma have also been reported. In
these cases, germline mutations in melanoma predispos-
ing genes are rarely detected7,9–11. Therefore, it is evident
that some other genetic or epigenetic factors are active in
MPM to fuel multiple events of melanocytic
transformation.
In this study, we provide the first comprehensive
molecular characterization of MPMs by analyzing their
miRNome with a small RNA-seq approach. The global
miRNA expression reflects the mRNA expression of cells
and tissues, with the advantage of being assessable in
FFPE tissues, which is the typical available tissue for thin
melanomas. Our analysis revealed a specific expression
pattern of multiple melanoma tumors when compared to
single CM. MPM miRNome is more similar to BN, thus
suggesting a less aggressive and more differentiated phe-
notype. We observed no distinct miRNA pattern in
MPMs with or without a recognized family history of
melanoma. We validated a panel of miRNAs in a larger
cohort, including also multiple tumors from the same
patient, obtaining a panel of miRNAs differentially
expressed in tumors from the same patient.
Many studies have attempted to define the prognosis of
patients with MPMs and results are still controversial,
with studies stating that developing multiple melanomas
is associated with worse prognosis or the opposite43–45.
Recently, Grossman et al.46 revealed the potential reasons
for these controversies by analyzing with proper multi-
variate statistical analysis, the Surveillance, Epidemiology,
Fig. 5 Comparison of miR-125a-5p and miR-200b-3p isomiR expression in benign nevi (BN), cutaneous melanoma (CM), and multiple
primary melanoma (MPM). a Floating bar chart of miR-125a-5p isomiR expression. Canonical miR-125a-5p (hsa-miR-125a-5p|0|0) shows a lower
expression level and opposite expression trend in BN, CM, and MPM if compared to its shorter isomiR (hsa-miR-125a-5p|0|−2). Bars represent
min–max and median values. b Floating bar chart of miR-200b-3p isomiR expression showing the same expression trend for canonical miR-200b-3p
(hsa-miR-200b-3p|0|0) and its longer isomiR (hsa-miR-200b-3p|0|+1) in MPM groups. Canonical miR-200b-3p was not detected in CM samples. Bars
represent min–max and median values. c Box and whiskers graph representation of canonical miR-125a-5p expression assessed with miRCURY LNA
assay and overall expression of all miR-125a-5p isoforms, detected using miSCRIPT assay. Results show that the combined expression of miR-125a-5p
isoforms of levels is higher in MPM compared to CM. The bar shows minimum and maximum values; superimposed points represent all individual
values. d Before–after plot of canonical miR-125a-5p expression (miRCURY LNA assay) and all miR-125a-5p isoforms (miSCRIPT assay) show an
opposite trend in the first and second melanoma from the same patient. e Box and whiskers graph representation of canonical miR-200b-3p
expression assessed with miRCURY LNA assay and overall expression of all miR-200b-3p isoforms, detected using miSCRIPT assay. Results show that in
both there is a higher expression in MPM compared to CM. The bar shows minimum and maximum values; superimposed points represent all
individual values. f Before–after plot of canonical miR-200b-3p expression (miRCURY LNA assay) and all miR-200b-3p isoforms (miSCRIPT assay) show
both a higher expression in the second melanoma compared to the first and from the same patient.
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and End Results data, using a single matching method and
demonstrating that there is no substantial difference
among single and multiple melanoma patients. In this
study, we provide the evidence that MPMs, from a bio-
logical point of view, have a less invasive phenotype as
pointed out by the main regulatory pathways activated in
these tumors, thus providing further elements of discus-
sion to support MPM’s less aggressive behavior. It is
worth mentioning that miRNAs known to inhibit EMT
(e.g., miR-200 family, miR-205, miR-149)39,47,48 are more
expressed in MPMs compared to that in single melano-
mas. Tumor cells promote EMT to escape from their
microenvironment and migrate to new locations, and give
rise to metastases49. The acquisition of a mesenchymal
phenotype promotes the production of extracellular
matrix proteins, the resistance to apoptosis, the inva-
siveness, and the migration50. EMT results from the loss
of cell-to cell junctions, induced by the loss of E-cadherin;
the process is mediated by transcription factors, including
SNAIL, SLUG, SIP1, and E2A, and affected by regulatory
proteins such as TGFβ, EGF, PDGF, ERK/MAPK, PI3K/
AKT, SMADS, RHOB, β‐catenin, LEF, RAS, C‐FOS,
integrins β4, and integrin α551. Despite their origin from
neural crest-derived melanocytes, EMT has been reported
in melanoma cells, where it promotes the metastatic
phenotype of malignant melanocytes52,53. Caramel et al.53
described a switch in the expression of embryonic EMT
inducers that drives the development of malignant
melanoma. They found that EMT-inducing transcrip-
tion factors undergo a profound reorganization in favor
of TWIST1 and ZEB1 during melanoma metastatiza-
tion53. Another work has demonstrated that ZEB2 is
important for migration and melanocyte differentiation
in a mice model54. The inhibition of FOXM1 leads to an
antitumor effect in melanoma55. Moreover, many stu-
dies described the loss of E-cadherin in melanoma56,57;
E-cadherin is normally expressed by melanocytes and
mediates the adhesion between melanocytes and kera-
tinocytes58. Hao et al.59 observed a switch from E-
cadherin to N-cadherin expression in melanoma pro-
gression, a process regulated by phosphatidyl inositol 3-
kinase (PI3K) and phosphatase and tensin homolog
Fig. 6 Canonical hsa-miR-125a-5p|0|0) and hsa-miR-125a-5p|0|−2 isomiR expression across 32 TCGA tumor types. miR-125a isomiR is most
expressed in many cancer types. Box and whiskers graphs of canonical and shorter isoform of miR-125a-5p show variable expression levels,
represented here as log2 RPKM data, across 32 different cancer type. miR-125a-5p isoform is most abundant in many cancer types and shows a
specifically high canonical/isoform ratio in the melanoma (SKCM) group. The bar shows 1–99 percentile values. TCGA abbreviations: ACC,
adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and
endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphom;
ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma;
KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD,
lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic
adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma;
SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma;
UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
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(PTEN) through TWIST and SNAIL. In addition, the
ectopic expression of Cadherin 1 was associated with the
downregulation of adhesion receptors, such as MCAM/
MUC18 and β3 integrin subunit, resulting in suppres-
sion of melanoma cells invasion60.
Consistently, we examined the main cellular hubs
regulated by MPM-specific miRNAs and discovered that
they are centered in Toll-like receptor 4 (TLR4), integrin
α6 (ITGA6), and BTG2 proteins. miRNAs regulating
these hubs are mostly downregulated in MPMs and high
expression of these three genes is associated with a more
favorable prognosis in TCGA SKCM cohort.
ITGA6, also known as CD49f, is a transmembrane
glycoprotein adhesion receptor that mediates cell–matrix
and cell–cell interactions. ITGA6 was identified and
described as an important stem cell biomarker. Indeed, it
is the only common gene expressed in embryonic stem
cells, neural stem cells, and hematopoietic stem cells61,62.
It is also expressed in more than 30 stem cell populations,
including cancer stem cells63. ITGA6 can combine with
other integrins such as integrin β1 and integrin β4 to form
respectively integrin VLA-6 and TSP180. The role of
ITGA6 in melanoma is not clear but our observation
point toward its upregulation in MPMs upon miR-25 and
miR-29 downregulation.
BTG2 is part of the anti-proliferative BTG/TOB family
and its expression is p53 dependent64. This protein is
involved in several cellular processes, including cell cycle
regulation, DNA damage repair, cell differentiation, pro-
liferation, and apoptosis. However, its role is often cell-
type dependent65. In fact, BTG2 inhibits proliferation and
migration, acting as a tumor suppressor protein, in gastric
cancer cells66 and in lung cancer cells67, whereas in
bladder cancer it promotes cancer cell migration68. In B16
melanoma cells, it was shown that miR-21 promoted a
metastatic behavior through the downregulation of many
tumor suppressor proteins, including PTEN, PDCD4, and
BTG269. In MPMs, we observe the downregulation of
several miRNAs targeting BTG2, including miR-21-5p,
miR-146a-5p, miR-132-3p, and miR-15a-5p. Therefore,
an upregulation of BTG2 expression is to be expected.
TLR4 belongs to the TLR family and plays an important
role in inflammation and cancer. TLR4 protein is
expressed at very low levels in melanoma cells in vivo
(Human protein atlas) but its activation has been reported
to promote an inflammatory microenvironment and
tumor progression in vitro70. In addition, TLR4 is asso-
ciated with induction of proliferation and migration of
melanoma cells71. TLR4 plays an important role in mel-
anoma as well, because it interacts with TRIM44, a
negative prognostic factor in melanoma. In particular,
TRIM44 binds and stabilizes TLR4, leading to the acti-
vation of AKT/mTOR signaling, which results in EMT
promotion72. This biological role for TLR4 in melanoma
is partially in contrast with our observation of a better
survival in melanoma patients with higher TLR4 levels.
Finally, we extended our molecular investigation to
miRNA isoforms that were most abundant in our sam-
ples. According to the recent observation that miRNA
isoforms can discriminate human cancers36, we detected a
relevant number of miRNA variants in our dataset of
single and multiple melanomas. We expected the cano-
nical miRNAs (e.g., the sequences cataloged in miRBase),
to be the most abundant isoform of each miRNA. How-
ever, we found and showed that some isomiRs were up to
ten times more expressed than the canonical miRNA. We
identified highly expressed isomiRs belonging to three
important miRNA families: miR-30 family, miR-200
family, and miR-10 family. Canonical miRNAs, from
these family, were thoroughly described as key regulators
in cancer and melanoma73–76. The functional role of the
isomiRs from these families is still unknown. We can
speculate that, similar to protein-coding gene isoforms,
which were discovered to play an important role in bio-
logical diversity and evolution77, isomiRs could have
relevant functional roles as well. Cloonan et al. studied the
role of two isomiRs of miR-10 family23, which were
detected also in our dataset but with a low isomiR/
canonical ratio: hsa-miR-10a-5p|+1|+1 (ratio= 0.12) and
hsa-miR-10b-5p|+1|+1 (ratio= 0.26) (Supplementary
Fig. 4). They suggested that the canonical miRNA works
together with its isomiRs to increase the signal-to-noise
ratio in miRNA–mRNA targeting23.
We analyzed two isomiRs (hsa-miR-125a-5p|0|−2 and
hsa-miR-200b-3p|0|+1) highly expressed in our dataset.
Specifically, we focused our analysis on the specific iso-
form of miR-125a-5p, lacking two nucleotides at the 3′-
end, because it has a different expression trend in our
groups (BN, CM, and MPM) if compared to its canonical
form and resulted to be significantly differentially
expressed in MPMs. This isoform is highly abundant in
melanoma, as we confirmed by analyzing its levels across
32 tumor types from the TCGA database, and the ratio
between miR-125a-5p isoform and the canonical form is
broader in TCGA SKCM tumors (range 0.1–1100 times)
and two to six logs more abundant in nevi and melanomas
in our study. Moreover, we detected a specific dysregu-
lation of the isoform, but not the canonical form, in
multiple melanomas. Bioinformatic analyses revealed that
miR-125a-5p shorted isoform putatively loses the ability
to target and regulate a group of genes specifically
involved in cell adhesion and cell differentiation. In par-
ticular, there seems to be lack of regulation of genes
involved in neuronal differentiation. Indeed, miR-125a is
the human ortholog of lin-4, the very first miRNA iden-
tified in Caenorhabditis elegans in 199378. In mammals,
miR-125 is expressed in embryonic stem cells and pro-
mote cell differentiation. Specifically, miR-125 has a
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specific role in adult nervous system development and
neuronal differentiation79,80. We speculated that the
imbalance between major miR-125 isoforms in melano-
cytes could reflect a major role for miR-125 in melanocyte
development and differentiation from the neural crest81,
differentiating this lineage from other common ancestor
cells. This role could be consequently reflected in mela-
noma development and progression.
Overall, we provide here a comprehensive character-
ization of miRNA/isomiR dysregulation and regulatory
network in single primary melanomas and MPMs. The
pattern of miRNA alterations supports a less aggressive
phenotype of MPMs, whereas isomiR-125a-5p levels
proved to be enriched in melanoma and differentially
expressed in MPMs, thus confirming the relevance of
small noncoding RNA alterations in this fascinating—but
poorly studied—melanoma subtype. Our observations
about non-random dysregulation of specific miRNA iso-
forms in melanoma pose the basis for further functional
studies.
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